Katakam B, Chiramel M, Gulati R, Gupta M, Munisamy M, Ranugha P
Indian Dermatol Online J. 2023; 14(2):172-186.
PMID: 37089858
PMC: 10115319.
DOI: 10.4103/idoj.idoj_52_22.
Kim J, Lam J
Drugs Context. 2021; 10.
PMID: 33889196
PMC: 8029639.
DOI: 10.7573/dic.2020-12-6.
Zhao Z, Liu C, Wang Q, Wu H, Zheng J
Ann Transl Med. 2021; 9(2):116.
PMID: 33569418
PMC: 7867894.
DOI: 10.21037/atm-20-5359.
Chen Z, Wang Q, Zhu Y, Zhou L, Xu T, He Z
Ann Transl Med. 2020; 7(22):692.
PMID: 31930093
PMC: 6944559.
DOI: 10.21037/atm.2019.10.47.
Prasad A, Sinha A, Kumar B, Prasad A, Kumari M
Pan Afr Med J. 2019; 32:155.
PMID: 31303926
PMC: 6607273.
DOI: 10.11604/pamj.2019.32.155.16760.
Central Effects of Beta-Blockers May Be Due to Nitric Oxide and Hydrogen Peroxide Release Independently of Their Ability to Cross the Blood-Brain Barrier.
Laurens C, Abot A, Delarue A, Knauf C
Front Neurosci. 2019; 13:33.
PMID: 30766473
PMC: 6365417.
DOI: 10.3389/fnins.2019.00033.
Interventions for infantile haemangiomas of the skin.
Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H
Cochrane Database Syst Rev. 2018; 4:CD006545.
PMID: 29667726
PMC: 6513200.
DOI: 10.1002/14651858.CD006545.pub3.
Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management.
Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L
Sci Rep. 2018; 8(1):4264.
PMID: 29523832
PMC: 5844887.
DOI: 10.1038/s41598-018-22787-8.
[Research progresses in the pathogenesis, diagnosis and treatment of infantile hemangioma with PHACE syndrome].
Peng S, Yang K, Chen S, Ji Y
Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19(12):1291-1296.
PMID: 29237532
PMC: 7389804.
Advances in the Medical Management of Vascular Anomalies.
Ricci K
Semin Intervent Radiol. 2017; 34(3):239-249.
PMID: 28955113
PMC: 5615390.
DOI: 10.1055/s-0037-1604297.
Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children.
Von Alvensleben J, LaPage M, Caruthers R, Bradley D
Pediatr Cardiol. 2016; 38(3):525-530.
PMID: 27995288
DOI: 10.1007/s00246-016-1544-y.
Cardiovascular drugs in the treatment of infantile hemangioma.
Fernandez-Pineda I, Williams R, Ortega-Laureano L, Jones R
World J Cardiol. 2016; 8(1):74-80.
PMID: 26839658
PMC: 4728108.
DOI: 10.4330/wjc.v8.i1.74.
Treatment of infantile haemangiomas: recommendations of a European expert group.
Hoeger P, Harper J, Baselga E, Bonnet D, Boon L, Ciofi Degli Atti M
Eur J Pediatr. 2015; 174(7):855-65.
PMID: 26021855
DOI: 10.1007/s00431-015-2570-0.
Infantile hemangioma in a v2 distribution: treatment with nadolol.
Giberson M, Hayes R
J Family Med Prim Care. 2015; 4(1):135-6.
PMID: 25811006
PMC: 4366987.
DOI: 10.4103/2249-4863.152272.
Biology of infantile hemangioma.
Itinteang T, Withers A, Davis P, Tan S
Front Surg. 2015; 1:38.
PMID: 25593962
PMC: 4286974.
DOI: 10.3389/fsurg.2014.00038.
Beta-blockers as therapy for infantile hemangiomas.
Nguyen H, Pickrell B, Wright T
Semin Plast Surg. 2014; 28(2):87-90.
PMID: 25045334
PMC: 4078206.
DOI: 10.1055/s-0034-1376259.
Signaling pathways in the development of infantile hemangioma.
Ji Y, Chen S, Li K, Li L, Xu C, Xiang B
J Hematol Oncol. 2014; 7:13.
PMID: 24479731
PMC: 3913963.
DOI: 10.1186/1756-8722-7-13.
Beta-blockers versus corticosteroids in the treatment of infantile hemangioma: an evidence-based systematic review.
Xu S, Jia R, Zhang W, Zhu H, Ge S, Fan X
World J Pediatr. 2013; 9(3):221-9.
PMID: 23929254
DOI: 10.1007/s12519-013-0427-z.
β-blockers: a novel class of antitumor agents.
Ji Y, Chen S, Xiao X, Zheng S, Li K
Onco Targets Ther. 2012; 5:391-401.
PMID: 23226026
PMC: 3513911.
DOI: 10.2147/OTT.S38403.
